First CAR T-cell therapy for multiple myeloma: AbecmaMarch 29, 2021Multiple MyelomaLymphoma & Plasma Cell Disorders
FDA scrutinizes cancer therapies granted accelerated approvalMarch 18, 2021Breast CancerGenitourinary CancerLung CancerLymphoma & Plasma Cell DisordersMultiple MyelomaOncologyHematology
Don’t delay: Cancer patients need both doses of COVID vaccineMarch 15, 2021Multiple MyelomaAMLBreast CancerGenitourinary CancerHead & Neck/Thyroid CancersLeukemia, Myelodysplasia, TransplantationLung Cancer
‘Phenomenal’ results with CAR T cells in R/R multiple myelomaMarch 4, 2021Multiple MyelomaLymphoma & Plasma Cell DisordersHematologyOncology
Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplantDecember 18, 2020Multiple MyelomaLymphoma & Plasma Cell DisordersHematologyOncology
Study found dual-targeted CAR T highly active against relapsed/refractory multiple myelomaDecember 15, 2020Multiple MyelomaLymphoma & Plasma Cell DisordersOncology
Extended virus shedding after COVID-19 in some patients with cancerDecember 10, 2020Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple Myeloma
Durable responses with anti-BCMA CAR T-cell for multiple myelomaDecember 6, 2020Multiple MyelomaLymphoma & Plasma Cell DisordersHematologyOncology
COVID-19–related outcomes poor for patients with hematologic disease in ASH registryDecember 5, 2020Multiple MyelomaHematology
Circulating miRNA could be a potential biomarker for early diagnosis of MMNovember 24, 2020Multiple MyelomaLymphoma & Plasma Cell DisordersOncology
Home care for bortezomib safe and reduces hospital visits in myeloma patientsNovember 11, 2020Multiple MyelomaLymphoma & Plasma Cell Disorders
Survey quantifies COVID-19’s impact on oncologySeptember 20, 2020Breast CancerLung CancerLeukemia, Myelodysplasia, TransplantationHead & Neck/Thyroid CancersGenitourinary CancerMelanomaLymphoma & Plasma Cell Disorders
Statins linked to improved survival in multiple myelomaSeptember 10, 2020Multiple MyelomaLymphoma & Plasma Cell Disorders
In-Depth Look at a Community- Based Population of Multiple Myeloma (MM) Patients Undergoing an in-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib in the United States (US) MM-6 StudySeptember 2, 2020OncologyMultiple MyelomaHematology
Effective Pain Control With Very Low Dose Palliative Radiotherapy for Multiple Myeloma Patients With Osseous LesionsSeptember 1, 2020OncologyMultiple MyelomaHematology
